Cargando…
Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature
Langerhans cell histiocytosis (LCH) is a diagnostic and therapeutic challenge. We report on a rare case of its primary oral manifestation that was treated successfully with the BRAF-specific agent, vemurafenib, after insufficient standard LCH treatment. This case underlines the importance of proper...
Autores principales: | Neckel, Norbert, Lissat, Andrej, von Stackelberg, Arendt, Thieme, Nadine, Doueiri, Mohemed-Salim, Spors, Birgit, Beck-Broichsitter, Benedicta, Heiland, Max, Raguse, Jan-Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801882/ https://www.ncbi.nlm.nih.gov/pubmed/31666812 http://dx.doi.org/10.1177/1758835919878013 |
Ejemplares similares
-
New somatic BRAF splicing mutation in Langerhans cell histiocytosis
por: Héritier, Sébastien, et al.
Publicado: (2017) -
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
por: Donadieu, Jean, et al.
Publicado: (2019) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023) -
Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
por: Holst, Johanne Marie, et al.
Publicado: (2021) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020)